Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats

G J KONTOGHIOGHES,* L SHEPPARD,* A V HOFFBRAND,*
J CHARALAMBOUS,† J TIKERPAE,‡ M J PIPPARD‡

*From the *Department of Haematology, Royal Free Hospital School of Medicine, London, the †School of Chemistry, The Polytechnic of North London, and the ‡Section of Haematology, Medical Research Council Clinical Research Centre, Northwick Park Hospital, Harrow, Middlesex*

SUMMARY A novel iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, and desferrioxamine were compared for their ability to remove iron and for their site of action in iron release in rats. Repeated intraperitoneal injections of the chelators in rats with widespread tissue labelling by ^{59}Fe derived from transferrin showed comparable ^{59}Fe mobilisation by each chelator in normal and iron loaded rats. Specific labelling of a chelatable "cold" iron pool in hepatocytes by ^{59}Fe derived from ferritin showed this pool to be equally accessible to parenteral doses of both chelators and also to oral 1,2-dimethyl-3-hydroxypyrid-4-one, which is an effective oral iron chelating agent that removes iron from parenchymal cells. This and other α -ketohydroxypyridines need further development as potential therapeutic agents in human iron overload.

The treatment of iron overload in transfusion dependent thalassaemia using desferrioxamine is expensive¹ and hence unobtainable in most parts of the world where the disease is common. Furthermore, the need to administer desferrioxamine by continuous subcutaneous infusion often leads to poor compliance with the treatment.² Consequently, there is a need for a new, cheap, orally active, non-toxic iron chelator. The α -ketohydroxypyridines³ are a promising group of iron chelators which have been shown to remove iron from transferrin,⁴ and ferritin⁵ in vitro, and from mice^{6,7} and rabbits,⁸ when administered orally and parenterally.

Our studies compared the iron chelating ability of desferrioxamine and 1,2-dimethyl-3-hydroxypyrid-4-one (L_1) in rats, being particularly concerned with determining the effect of repeated parenteral doses of the drugs in normal and iron loaded animals; the main site of action of the drugs; and the relative efficiency of oral and parenteral doses of L_1 . To follow iron mobilisation by the drugs two different tech-

niques for labelling the rats with ^{59}Fe were used: in the first, injection of ^{59}Fe -labelled transferrin distributed radioiron throughout the body, most particularly in the red cells and liver; and in the second, ^{59}Fe -labelled ferritin was used to label specifically a pool of metabolically active chelatable iron within rat liver parenchymal cells.^{9,10}

Material and methods

L_1 was prepared according to the method of Kontoghiorghe.³ Desferrioxamine was obtained from Ciba-Geigy, Horsham, Sussex; phosphate buffered saline from Oxoid, Basingstoke; iron dextran (Imferon) from Fisons, Loughborough; human transferrin from Sigma, and ^{59}Fe citrate from Amersham International. Male Sprague Dawley rats were used for the ^{59}Fe transferrin and female Sprague Dawley rats for the ^{59}Fe ferritin studies. All the rats were fed with grain harvested 41B pellets.

PREPARATION OF ^{59}Fe -TRANSFERRIN AND ^{59}Fe -FERRITIN

^{59}Fe citrate (62.5 μCi , 5.65 μg Fe, 625 μl) was first added to apotransferrin (75 mg in 2 ml phosphate

buffered saline). After 30 minutes of incubation aqueous ferrous ammonium sulphate (1 ml, 96 µg Fe) and double strength phosphate buffered saline (1 ml) were added stepwise at five minute intervals before making a total volume of 12.5 ml with phosphate buffered saline. The resulting pink ^{59}Fe transferrin solution was incubated for a further two hours before being given intravenously to rats.

Rat liver ferritin was labelled with ^{59}Fe in vivo. It was isolated from the heat supernatant of a liver homogenate prepared in 0.25M acetate buffer (pH 4.8) and purified by ultracentrifugation.¹¹

STUDIES USING ^{59}Fe -TRANSFERRIN

Nine rats were given intraperitoneal injections of iron dextran every three days over two weeks, amounting to a total of 140 mg iron for each rat. Five weeks after the last injection the nine iron loaded and 14 normal rats were labelled with ^{59}Fe by injecting ^{59}Fe transferrin (2 µCi, 400 µl) via the tail vein, and divided into five cages (three of normal and two of iron loaded rats). Subsequent total ^{59}Fe excretion (urine plus faeces) in eight separate weekly collections of the cage litter, and the radioactivity remaining in each group of rats at the end of the studies, were measured in a large volume gamma counter. About 200 mg/kg of chelators were given by daily intraperitoneal injection during the third and sixth weeks after ^{59}Fe -transferrin labelling. One control group received no chelator injections.

STUDIES USING ^{59}Fe -LABELLED FERRITIN

^{59}Fe -ferritin iron (7.5 µg iron, 0.2 µCi) was injected intravenously via the lateral tail vein two hours before the test chelator was given. Food was removed from the test rats (weight 180–220 g) during the night before each experiment, although free access to water was permitted. After administration of the chelator rats were placed in metabolic cages for collection of urine and faeces during the subsequent four hours, after which the animals were killed.¹¹

In some studies bile cannulation was carried out under Hypnorm (Fentanyl citrate, 0.315 mg/ml; Fluanisone, 10 mg/ml, Crown Chemicals, Lamburnhurst, Kent) and diazepam anaesthesia. PE50 tubing was inserted into the bile duct above the pancreas. During collection of bile the anaesthesia was repeated as necessary, and fluid replacement equal to the bile drain (1 ml/hour) was given by subcutaneous injection of saline. The intravenous injection of ^{59}Fe -ferritin was given immediately after completion of the operation, followed at two hours by administration of the chelator.

The rats were killed at six hours by exsanguination from the abdominal aorta followed by perfusion with 20 ml of physiological saline before removal of the

organs for ^{59}Fe counting. Radioactivity in the liver, gut and contents, or bile, faeces, blood, residual carcass and urine was determined using an automatic well gamma counter. Tails and residual carcasses were counted separately in a large volume counter with corrections for differences in geometry. The percentage of the total injected counts in each organ was standardised to a total recovery of 100%. Urine and bile iron content was measured colorimetrically using bathophenanthroline sulphonate. Liver non-haem iron was determined in homogenates of the liver using a modification of the hydrochloric acid method of Kaldor.¹²

Iron chelators were prepared in aqueous solution to give a final dose of 40 mg in 0.5 ml. Intramuscular doses were given into the hind limb and oral doses were given using a stomach tube.

Results

STUDIES USING ^{59}Fe -LABELLED TRANSFERRIN

After the administration of ^{59}Fe -transferrin ^{59}Fe excretion in control rats was maximal in the first two weeks (fig 1). It then remained relatively stable, declining only slowly over the rest of the study period.

In normal rats administration of intraperitoneal L_1 (fig 1) or desferrioxamine (fig 1) caused a substantial increase in the overall ^{59}Fe excretion. ^{59}Fe excretion was higher in the third week than the sixth week. In iron loaded rats treated with L_1 (fig 1) and desferrioxamine (fig 1) the ^{59}Fe excretion was similar in amount and profile to that seen in the normal animals. Most of the ^{59}Fe remained in the rats even after prolonged chelation (table 1). Weight gain was not affected by chelator treatment and all the rats were alive seven months later. Within minutes of injection, however, L_1 produced hypersalivation, which continued for one to two hours. This was also seen after oral and intramuscular injection of L_1 in the ^{59}Fe -ferritin study, in contrast to the injections of desferrioxamine which had no obvious adverse effects. In a preliminary study the administration of L_1 to normal rats under anaesthetic (Hypnorm) did not cause any salivation.

STUDIES USING ^{59}Fe -FERRITIN

When control rats were killed six hours after intravenous ^{59}Fe -ferritin injection, over 90% of the ^{59}Fe remained in the liver (fig 2). With desferrioxamine or L_1 given two hours after the ^{59}Fe injection, about 40% of the ^{59}Fe was mobilised from the liver into the gut (fig 2). Oral and intramuscular L_1 were of comparable efficiency.

The ^{59}Fe appearing in the gut was derived from biliary excretion (table 2). Carrier iron excretion in

Fig 1 Weekly ^{59}Fe excretion profiles in groups of normal (A, B, C) and iron loaded (D, E) ^{59}Fe transferrin. Intraperitoneal injections of L_1 (groups A, D) or desferrioxamine (groups B, E) were given during weeks 3 and 6 at a dose of about 200 mg/kg/day. Group C received no chelator injections.

the bile was also greatly increased with both chelators, and only small amounts of iron were mobilised into the urine. There was no additive effect when combined intramuscular injections of 40 mg of desferrioxamine and L_1 were given. In addition, the inverse relation between the dilution of the ^{59}Fe by cold iron in the bile (bile specific activity) and the total liver non-haem iron content was similar with each chelator and with their combination (fig 3).

Discussion

These studies have shown that in both models desferrioxamine and L_1 produce comparable chelation of iron. In the rats allowed to reach a steady state of ^{59}Fe excretion after labelling with ^{59}Fe -transferrin, however, the absolute amounts of ^{59}Fe mobilised were small, despite repeated injections (table 1). In addition, iron loading with iron dextran (initially cleared to macrophages) had little effect on the amount of ^{59}Fe excreted, suggesting that the chelata-

ble ^{59}Fe was largely independent of or non-diluted by this iron dextran storage pool. In contrast, large amounts of ^{59}Fe were available to both L_1 and desferrioxamine using the ^{59}Fe ferritin model, where the ^{59}Fe is released transiently within a chelatable pool within hepatocytes.¹¹ Oral and parenteral doses of L_1 were comparable to desferrioxamine in their efficiency of mobilising ^{59}Fe (fig 2). In both cases most of the ^{59}Fe was excreted in the bile. The lack of any additive effect with the two drugs at the dose used and the similar relation between bile ^{59}Fe and carrier iron with both chelators (fig 3) suggest that the drugs chelated iron from the same site within hepatocytes. Like desferrioxamine, L_1 therefore seems to be able to penetrate the liver parenchymal cells which are a major site of iron storage in human primary or secondary haemochromatosis.

During the present studies, no deaths or evidence of failure to thrive (table 1) were observed in either normal or iron loaded animals. Pronounced salivation was observed with either parenteral or oral adminis-

Fig 2 Distribution of ⁵⁹Fe six hours after intravenous administration of ⁵⁹Fe-ferritin. Iron chelators were given after two hours (1: control, no chelator; 2: desferrioxamine 40 mg intramuscularly; 3: L₁ 40 mg intramuscularly; 4: L₁ 40 mg orally). Each column represents one rat. Urine ⁵⁹Fe was less than 0.5% in all cases.

Fig 3 Relation between bile specific activity (per cent injected ⁵⁹Fe in bile divided by μM iron in bile) and liver non-haem iron content. Each point represents results from one rat (● desferrioxamine 40 mg intramuscularly; ○ L₁ 40 mg intramuscularly; ■ desferrioxamine 40 mg intramuscularly plus L₁ 40 mg intramuscularly).

tration of L₁, however, an effect which was not seen in mice^{6,7} and rabbits.⁸ It remains to be determined whether this adverse effect is related to the bitter taste of the drug and also whether other α-ketohydroxypyridine analogues^{6,13} of L₁ may have the same effect. Nevertheless, the present demonstration that in the rat L₁ is of equal efficiency to desferrioxamine during a long term treatment and also that it acts as a parenchymal iron chelating agent, which has the additional advantage of oral

activity, should stimulate the further investigation into the development of L₁ or its analogues¹³ as potential agents for the treatment of iron overload in human disease.

This work was supported by the United Kingdom Thalassaemia Society. We thank S Chambers, and A Dodd for their technical assistance, DP Moore and AJ Palmer for helping in the animal studies, and Mrs J Wilkinson for word processing.

Table 1 Effect of chelators on growth and ⁵⁹Fe content of ⁵⁹Fe-transferrin labelled rats

Group	(n =)	Chelator	Dose (in weeks 3, 6) (mg/day/rat)	Rat weights (g) before study		Rat weights (g) after study		Rat ⁵⁹ Fe content (cpm) after study
				Mean	Range	Mean	Range	
Normal rats:								
A	5	L ₁	40*	220	(180–240)	448	(400–518)	30802
B	5	Desferrioxamine	40*	220	(180–240)	466	(431–502)	28110
C	4			436	(400–500)	619	(610–635)	30941
Iron loaded rats:								
D	5	L ₁	80†	412	(350–460)	546	(504–595)	31864
E	4	Desferrioxamine	80†	412	(350–460)	508	(459–615)	32656

*Group A received 5 × 40 mg doses and 1 × 20 mg dose in week 3 and 6 × 40 mg doses in week 6; group B received 7 × 40 mg doses in both weeks 3 and 6.

†Group D received 5 × 80 mg doses and 1 × 40 mg dose in week 3 and 6 × 80 mg doses in week 6; group E received 7 × 80 mg doses in both weeks 3 and 6.

Table 2 Distribution of ^{59}Fe derived from ferritin and cold iron excretion in bile cannulated rats*

Chelator	(n =)	% ^{59}Fe (range)			Iron (μM) (range)		
		Liver	Bile	Urine	Liver	Bile	Urine
Control	1	90.2	0.70	0.01	14.7	0.09	0.01
Desferrioxamine intramuscularly	3	43.9 (36.1–50.3)	47.2 (41.2–56.8)	0.8 (0.2–1.7)†	17.6 (13.3–20.6)	1.52 (1.03–1.83)	0.12 (0.05–0.25)†
L ₁ intramuscularly	3	45.6 (32.2–61.2)	46.2 (27.3–60.8)	0.4 (0.2–0.5)	18.5 (13.8–23.7)	1.56 (0.71–2.00)	0.09 (0.09–0.09)
Desferrioxamine intramuscularly + L ₁ intramuscularly	2	48.5 (37.0–60.0)	40.2 (33–47.4)	2.45 (0.1–4.8)†	17.9 (16.4–19.4)	1.14 (1.03–1.26)	0.22 (0.03–0.41)†

*Chelators were given at a dose of 40 mg two hours after intravenous ^{59}Fe injection and animals were killed after a further four hours.

†Wide variation in urine values is due to the effects of transient biliary obstruction associated with the bile cannulation procedure.

References

- 1 Brown EG. Thalassaemia. In: Brewer GJ, ed. *Orphan drugs and orphan diseases. Clinical realities and public policy*. New York: Alan R Liss 1983:33–42.
- 2 Wolfe L. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassaemia major. *N Engl J Med* 1985;312:1600–3.
- 3 Kontoghiorghes GJ. The design of orally active iron chelators for the treatment of thalassaemia. Essex, University of Essex, 1982. (Thesis.)
- 4 Kontoghiorghes GJ. The study of iron mobilisation from transferrin using α -ketohydroxy heteroaromatic chelators. *Biochim Biophys Acta* 1986;869:141–6.
- 5 Kontoghiorghes GJ. Iron mobilisation from ferritin using α -oxohydroxy heteroaromatic chelators. *Biochem J* 1986;233:299–302.
- 6 Kontoghiorghes GJ. Dose response studies using desferrioxamine and orally active chelators in a mouse model. *Scand J Haematol* 1986;37:63–70.
- 7 Kontoghiorghes GJ. New orally active iron chelators. *Lancet* 1985;i:817.
- 8 Kontoghiorghes GJ, Hoffbrand AV. Orally active α -ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits. *Br J Haematol* 1986;62:607–13.
- 9 Hershko C, Cook JD, Finch CA. Storage iron kinetics III. Study of desferrioxamine action by selective radio-iron labels of RE and parenchymal cells. *J Lab Clin Med* 1973;81:876–8.
- 10 Pippard MJ, Johnson DJ, Finch CA. Hepatocyte iron kinetics in the rat, explored with an iron chelator. *Br J Haematol* 1982;52:211–24.
- 11 Pippard MJ, Johnson DK, Finch CA. A rapid assay for evaluation of iron chelating agents in rats. *Blood* 1981;58:685–92.
- 12 Kaldor I. Studies on intermediary iron metabolism V. The measurement of non-haemoglobin tissue iron. *Aust J Exp Biol Med Sci* 1954;32:795–800.
- 13 Kontoghiorghes GJ. Orally active α -ketohydroxypyridine iron chelators: studies in mice. *Mol Pharmacol* 1986;30:670–3.

Requests for reprints to: Dr G J Kontoghiorghes, Department of Haematology, Royal Free Hospital School of Medicine, Hampstead, London NW3 2QG, England.